Reviva Pharmaceuticals (RVPH) KOL Event summary

Introduction and agenda

• Fireside chat focused on brilaroxazine, a serotonin-dopamine modulator in late-stage development for schizophrenia and other CNS disorders, following recent positive Phase 3 data.

• The session included presentations, expert commentary, and a Q&A segment, with a hard stop after one hour.

KOL background and credentials

• Dr. Larry Ereshefsky has nearly 50 years in CNS drug development, with expertise in antipsychotics and clinical trial design.

• Dr. Mark Opler, a psychometrician and trialist, is Executive Director of the PANSS Institute and has extensive experience in psychiatric clinical trials.

Market insights and analysis

• Schizophrenia affects 24 million globally, with significant unmet needs due to partial or non-response and high discontinuation rates for current antipsychotics.

• The antipsychotic market is valued at $40 billion, dominated by five drugs capturing 80% of the market.